1. Home
  2. ORGN vs CMMB Comparison

ORGN vs CMMB Comparison

Compare ORGN & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Materials Inc.

ORGN

Origin Materials Inc.

HOLD

Current Price

$2.10

Market Cap

12.4M

Sector

Industrials

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$1.69

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORGN
CMMB
Founded
2008
2004
Country
United States
Israel
Employees
91
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.4M
11.2M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
ORGN
CMMB
Price
$2.10
$1.69
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
501.6K
43.1K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
101.67
EPS
N/A
0.04
Revenue
N/A
N/A
Revenue This Year
$503.74
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$42.50
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.87
52 Week High
$4.11
$3.86

Technical Indicators

Market Signals
Indicator
ORGN
CMMB
Relative Strength Index (RSI) 56.60 51.22
Support Level $0.35 $1.44
Resistance Level $4.11 $1.86
Average True Range (ATR) 0.36 0.13
MACD -0.13 0.01
Stochastic Oscillator 8.75 61.90

Price Performance

Historical Comparison
ORGN
CMMB

About ORGN Origin Materials Inc.

Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: